Category: News

Post

T2 Biosystems Reports Granting of Inducement Awards

LEXINGTON, Mass. , Jan. 08, 2019 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on January 2, 2019 it issued inducement awards to six new READ FULL TEXT

Post

Update on Admission

Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) READ FULL TEXT

Post

Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial

CAMBRIDGE, Mass. , Jan. 07, 2019 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections, and Everest Medicines READ FULL TEXT

Post

ContraFect’s Exebacase (CF-301) Improved Clinical Outcomes in Staphylococcus aureus Bacteremia including  Right-Sided Endocarditis Compared to Standard of Care Antibiotics Alone in a First-in-Patient Phase 2 Superiority Study

ContraFect’s Exebacase (CF-301) Improved Clinical Outcomes in Staphylococcus aureus Bacteremia including  Right-Sided Endocarditis Compared to Standard of Care Antibiotics Alone in a First-in-Patient Phase 2 Superiority Study READ FULL TEXT

Post

Nabriva Therapeutics Announces Acceptance of the New Drug Application for Intravenous CONTEPO™ to Treat Complicated Urinary Tract Infections by FDA

-PDUFA action date set for June 30, 2019- DUBLIN, Ireland , Jan. 04, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced that READ FULL TEXT

Post

SCYNEXIS Provides Year-end Update and Outlines Plans for 2019

Initiated VANISH Phase 3 program of oral ibrexafungerp in acute VVC; top-line data expected in 1H 2020 with potential NDA filing in 2H 2020 Initiation of recurrent VVC Phase 3 trial planned for 1H 2019 Continued advancement of oral ibrexafungerp clinical development program in hospital-based invasive fungal infections Received non-dilutive state incentive cash benefit of...

Post

VenatoRx Pharmaceuticals Joins Antimicrobials Working Group

The Antimicrobials Working Group (AWG) announced the addition of VenatoRx Pharmaceuticals to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG’s membership to 15 antimicrobial drug companies. READ FULL TEXT